Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: FDA OHIP director

This article was originally published in The Gray Sheet

Executive Summary

FDA OHIP director: Lireka Joseph begins serving Aug. 11 as director of the Center for Devices and Radiological Health's Office of Health and Industry Programs. Joseph started her FDA career in 1979 as a medical radiation specialist in the agency's Bureau of Radiological Health and has held various posts in the center's Office of Training and Assistance (OHIP's predecessor), including assistant to the director and acting deputy director. For the past two years, Joseph has served in FDA's Office of the Commissioner as special assistant to the deputy commissioner for operations. She replaces CDRH Deputy Director for Regulations and Policy Joseph Levitt, who has been interim OHIP director since the retirement of former OHIP Director Jim Morrison. In addition, OHIP Division of Device User Programs and Systems Analysis Director Carol Vetter is slated to retire Sept. 31. Vetter's position has been filled for several months on a rotating detail basis by various CDRH staffers, which will continue until a permanent division director is named...

You may also be interested in...



Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims

Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel